In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

EGFR mutated lung cancer accounts for a significant subgroup of non-small-cell lung cancer (NSCLC). Over the last decade, multiple EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been developed to target mutated EGFR. However, there is little information regarding mutation specific potency of EGFR-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirano, Toshiyuki, Yasuda, Hiroyuki, Tani, Tetsuo, Hamamoto, Junko, Oashi, Ayano, Ishioka, Kota, Arai, Daisuke, Nukaga, Shigenari, Miyawaki, Masayoshi, Kawada, Ichiro, Naoki, Katsuhiko, Costa, Daniel B., Kobayashi, Susumu S., Betsuyaku, Tomoko, Soejima, Kenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770737/
https://www.ncbi.nlm.nih.gov/pubmed/26515464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770737/
https://www.ncbi.nlm.nih.gov/pubmed/26515464

Ejemplares similares